Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	fructose-bisphosphate aldolase activity	ALDOA ALDOC	8.94e-06	3	35	2	GO:0004332
GeneOntologyMolecularFunction	aldehyde-lyase activity	ALDOA ALDOC	1.63e-04	11	35	2	GO:0016832
GeneOntologyBiologicalProcess	negative regulation of release of cytochrome c from mitochondria	HGF TRIAP1 GPX1	7.74e-06	23	35	3	GO:0090201
GeneOntologyBiologicalProcess	regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling	MET HGF	2.79e-05	5	35	2	GO:0060665
GeneOntologyBiologicalProcess	myoblast proliferation	MET HGF GPX1	5.27e-05	43	35	3	GO:0051450
GeneOntologyBiologicalProcess	regulation of release of cytochrome c from mitochondria	HGF TRIAP1 GPX1	8.31e-05	50	35	3	GO:0090199
GeneOntologyBiologicalProcess	fructose 1,6-bisphosphate metabolic process	ALDOA ALDOC	1.00e-04	9	35	2	GO:0030388
GeneOntologyBiologicalProcess	regulation of branching involved in salivary gland morphogenesis	MET HGF	1.52e-04	11	35	2	GO:0060693
GeneOntologyBiologicalProcess	lipoxygenase pathway	ALOX15 GPX1	1.52e-04	11	35	2	GO:0019372
GeneOntologyBiologicalProcess	carbohydrate transmembrane transport	ABCB11 MET AHI1 ACE	1.83e-04	168	35	4	GO:0034219
GeneOntologyBiologicalProcess	hepatocyte growth factor receptor signaling pathway	MET HGF	1.83e-04	12	35	2	GO:0048012
GeneOntologyBiologicalProcess	mesenchymal-epithelial cell signaling	MET HGF	1.83e-04	12	35	2	GO:0060638
GeneOntologyBiologicalProcess	release of cytochrome c from mitochondria	HGF TRIAP1 GPX1	1.90e-04	66	35	3	GO:0001836
GeneOntologyBiologicalProcess	negative regulation of hydrogen peroxide-mediated programmed cell death	MET HGF	2.16e-04	13	35	2	GO:1901299
GeneOntologyBiologicalProcess	carbohydrate transport	ABCB11 MET AHI1 ACE	2.69e-04	186	35	4	GO:0008643
GeneOntologyBiologicalProcess	positive regulation of supramolecular fiber organization	MET USP8 ALOX15 GPX1	3.29e-04	196	35	4	GO:1902905
GeneOntologyBiologicalProcess	fructose metabolic process	ALDOA ALDOC	3.31e-04	16	35	2	GO:0006000
GeneOntologyBiologicalProcess	regulation of hydrogen peroxide-mediated programmed cell death	MET HGF	4.70e-04	19	35	2	GO:1901298
GeneOntologyCellularComponent	photoreceptor distal connecting cilium	AHI1 RPGR	5.69e-05	7	35	2	GO:0120206
GeneOntologyCellularComponent	ciliary transition zone	CPLANE2 AHI1 RPGR	3.35e-04	81	35	3	GO:0035869
GeneOntologyCellularComponent	sperm flagellum	MET RPGR ALDOA ACE	4.36e-04	214	35	4	GO:0036126
GeneOntologyCellularComponent	9+2 motile cilium	MET RPGR ALDOA ACE	6.50e-04	238	35	4	GO:0097729
Domain	Glycolytic	ALDOA ALDOC	9.64e-06	3	34	2	PF00274
Domain	Aldolase_I_AS	ALDOA ALDOC	9.64e-06	3	34	2	IPR029768
Domain	ALDOLASE_CLASS_I	ALDOA ALDOC	9.64e-06	3	34	2	PS00158
Domain	FBA_I	ALDOA ALDOC	9.64e-06	3	34	2	IPR000741
Domain	zf-C2H2_6	ZNF317 ZNF582 ZNF566 ZNF44	2.44e-03	314	34	4	PF13912
Domain	-	ALDOA ALDOC	2.65e-03	42	34	2	3.20.20.70
Domain	Aldolase_TIM	ALDOA ALDOC	2.90e-03	44	34	2	IPR013785
Domain	PSI	MET ITGB7	2.90e-03	44	34	2	IPR016201
Domain	PSI	MET ITGB7	3.17e-03	46	34	2	SM00423
Domain	KRAB	ZNF317 ZNF582 ZNF566 ZNF44	3.91e-03	358	34	4	PS50805
Domain	KRAB	ZNF317 ZNF582 ZNF566 ZNF44	3.91e-03	358	34	4	PF01352
Domain	KRAB	ZNF317 ZNF582 ZNF566 ZNF44	4.35e-03	369	34	4	SM00349
Domain	KRAB	ZNF317 ZNF582 ZNF566 ZNF44	4.40e-03	370	34	4	IPR001909
Domain	zf-C2H2	ZNF317 ZNF582 ZNF518A ZNF566 ZNF44	7.90e-03	693	34	5	PF00096
Domain	Znf_C2H2/integrase_DNA-bd	ZNF317 ZNF582 ZNF518A ZNF566 ZNF44	7.95e-03	694	34	5	IPR013087
Domain	ZINC_FINGER_C2H2_2	ZNF317 ZNF582 ZNF518A ZNF566 ZNF44	1.24e-02	775	34	5	PS50157
Domain	ZINC_FINGER_C2H2_1	ZNF317 ZNF582 ZNF518A ZNF566 ZNF44	1.26e-02	777	34	5	PS00028
Pathway	REACTOME_NEGATIVE_REGULATION_OF_MET_ACTIVITY	MET HGF USP8	1.13e-05	21	30	3	M27645
Pathway	REACTOME_NEGATIVE_REGULATION_OF_MET_ACTIVITY	MET HGF USP8	1.13e-05	21	30	3	MM15347
Pathway	REACTOME_MET_INTERACTS_WITH_TNS_PROTEINS	MET HGF	4.36e-05	5	30	2	M27775
Pathway	REACTOME_MET_ACTIVATES_PTPN11	MET HGF	4.36e-05	5	30	2	M27758
Pathway	REACTOME_MET_ACTIVATES_PTPN11	MET HGF	4.36e-05	5	30	2	MM15503
Pathway	REACTOME_MET_INTERACTS_WITH_TNS_PROTEINS	MET HGF	4.36e-05	5	30	2	MM15514
Pathway	REACTOME_MET_ACTIVATES_PI3K_AKT_SIGNALING	MET HGF	6.53e-05	6	30	2	M27741
Pathway	REACTOME_MET_RECEPTOR_ACTIVATION	MET HGF	6.53e-05	6	30	2	M27644
Pathway	REACTOME_SYNTHESIS_OF_15_EICOSATETRAENOIC_ACID_DERIVATIVES	ALOX15 GPX1	6.53e-05	6	30	2	M27141
Pathway	REACTOME_MET_RECEPTOR_ACTIVATION	MET HGF	6.53e-05	6	30	2	MM15346
Pathway	REACTOME_MET_ACTIVATES_PI3K_AKT_SIGNALING	MET HGF	6.53e-05	6	30	2	MM15489
Pathway	REACTOME_SYNTHESIS_OF_15_EICOSATETRAENOIC_ACID_DERIVATIVES	ALOX15 GPX1	6.53e-05	6	30	2	MM14862
Pathway	REACTOME_SYNTHESIS_OF_12_EICOSATETRAENOIC_ACID_DERIVATIVES	ALOX15 GPX1	9.13e-05	7	30	2	M27139
Pathway	REACTOME_SYNTHESIS_OF_12_EICOSATETRAENOIC_ACID_DERIVATIVES	ALOX15 GPX1	9.13e-05	7	30	2	MM14860
Pathway	PID_TCPTP_PATHWAY	MET HGF STAT1	9.44e-05	42	30	3	M91
Pathway	PID_P53_DOWNSTREAM_PATHWAY	MET HGF TRIAP1 GPX1	1.92e-04	137	30	4	M145
Pathway	REACTOME_MET_RECEPTOR_RECYCLING	MET HGF	1.95e-04	10	30	2	M27777
Pathway	KEGG_MEDICUS_REFERENCE_HGF_MET_PI3K_SIGNALING_PATHWAY	MET HGF	1.95e-04	10	30	2	M47401
Pathway	REACTOME_MET_ACTIVATES_RAS_SIGNALING	MET HGF	1.95e-04	10	30	2	MM15488
Pathway	REACTOME_MET_RECEPTOR_RECYCLING	MET HGF	1.95e-04	10	30	2	MM15516
Pathway	PID_FGF_PATHWAY	MET HGF STAT1	2.12e-04	55	30	3	M276
Pathway	REACTOME_MET_ACTIVATES_RAS_SIGNALING	MET HGF	2.38e-04	11	30	2	M27740
Pathway	REACTOME_MET_ACTIVATES_RAP1_AND_RAC1	MET HGF	2.38e-04	11	30	2	M27776
Pathway	REACTOME_MET_ACTIVATES_RAP1_AND_RAC1	MET HGF	2.38e-04	11	30	2	MM15515
Pathway	REACTOME_SIGNALING_BY_MET	MET HGF USP8	3.80e-04	67	30	3	MM15345
Pathway	KEGG_MEDICUS_REFERENCE_HGF_MET_RAS_ERK_SIGNALING_PATHWAY	MET HGF	4.52e-04	15	30	2	M47473
Pathway	REACTOME_SIGNALING_BY_MET	MET HGF USP8	6.17e-04	79	30	3	M27643
Pathway	REACTOME_MET_ACTIVATES_PTK2_SIGNALING	MET HGF	7.32e-04	19	30	2	MM15512
Pathway	WP_OXYLIPINS_PATHWAYS	ALOX15 GPX1	1.17e-03	24	30	2	MM17249
Pathway	KEGG_MEDICUS_REFERENCE_GLYCOLYSIS	ALDOA ALDOC	1.27e-03	25	30	2	M47623
Pathway	REACTOME_GLUCONEOGENESIS	ALDOA ALDOC	1.38e-03	26	30	2	MM15392
Pathway	REACTOME_GLUCONEOGENESIS	ALDOA ALDOC	1.38e-03	26	30	2	M13748
Pathway	KEGG_PENTOSE_PHOSPHATE_PATHWAY	ALDOA ALDOC	1.49e-03	27	30	2	M1386
Pathway	REACTOME_INTERLEUKIN_4_AND_INTERLEUKIN_13_SIGNALING	HGF STAT1 ALOX15	1.65e-03	111	30	3	M27609
Pathway	WP_EXTRACELLULAR_VESICLEMEDIATED_SIGNALING_IN_RECIPIENT_CELLS	MET HGF	1.72e-03	29	30	2	M39516
Pathway	REACTOME_MET_ACTIVATES_PTK2_SIGNALING	MET HGF	1.84e-03	30	30	2	M27772
Pathway	REACTOME_MET_PROMOTES_CELL_MOTILITY	MET HGF	1.84e-03	30	30	2	MM15517
Pathway	WP_EICOSANOID_METABOLISM_VIA_LIPOXYGENASES_LOX	ALOX15 GPX1	2.22e-03	33	30	2	MM15963
Pathway	BIOCARTA_MET_PATHWAY	MET HGF	2.22e-03	33	30	2	M19358
Pathway	BIOCARTA_MET_PATHWAY	MET HGF	2.22e-03	33	30	2	MM1494
Pathway	KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM	ALDOA ALDOC	2.35e-03	34	30	2	M15898
Pathway	WP_HEPATOCYTE_GROWTH_FACTOR_RECEPTOR_SIGNALING	MET HGF	2.35e-03	34	30	2	M39383
Pathway	PID_ARF6_PATHWAY	MET HGF	2.49e-03	35	30	2	M86
Pathway	REACTOME_MET_PROMOTES_CELL_MOTILITY	MET HGF	3.41e-03	41	30	2	M27778
Pathway	PID_ECADHERIN_STABILIZATION_PATHWAY	MET HGF	3.41e-03	41	30	2	M232
Pubmed	Four individually druggable MET hotspots mediate HGF-driven tumor progression.	MET HGF	9.84e-07	2	35	2	24865428
Pubmed	A unique population of bone marrow cells migrates to skeletal muscle via hepatocyte growth factor/c-met axis.	MET HGF	9.84e-07	2	35	2	16144866
Pubmed	Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.	MET HGF	9.84e-07	2	35	2	15678502
Pubmed	Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.	MET HGF	9.84e-07	2	35	2	20200025
Pubmed	Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.	MET HGF	9.84e-07	2	35	2	15192042
Pubmed	Consistent expression of HGF and c-met in the perinatal lung.	MET HGF	9.84e-07	2	35	2	16498238
Pubmed	A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation.	MET HGF	9.84e-07	2	35	2	9166406
Pubmed	Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice.	MET HGF	9.84e-07	2	35	2	22095660
Pubmed	Hepatocyte growth factor; expression, concentration and biological activity in chronic leg ulcers.	MET HGF	9.84e-07	2	35	2	15659325
Pubmed	Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development.	MET HGF	9.84e-07	2	35	2	19318497
Pubmed	Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway.	MET HGF	9.84e-07	2	35	2	27893712
Pubmed	Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer?	MET HGF	9.84e-07	2	35	2	20178463
Pubmed	Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis.	MET HGF	9.84e-07	2	35	2	8631159
Pubmed	Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist.	MET HGF	9.84e-07	2	35	2	18291418
Pubmed	Involvement of hepatocyte growth factor in branching morphogenesis of murine salivary gland.	MET HGF	9.84e-07	2	35	2	14517989
Pubmed	Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.	MET HGF	9.84e-07	2	35	2	25504327
Pubmed	HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma.	MET HGF	9.84e-07	2	35	2	17981731
Pubmed	Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence.	MET ACE	9.84e-07	2	35	2	23006961
Pubmed	Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy.	MET HGF	9.84e-07	2	35	2	21922134
Pubmed	Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.	MET HGF	9.84e-07	2	35	2	17992475
Pubmed	c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.	MET HGF	9.84e-07	2	35	2	23898085
Pubmed	Hepatocyte growth factor and myopia: genetic association analyses in a Caucasian population.	MET HGF	9.84e-07	2	35	2	19471602
Pubmed	Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue.	MET HGF	9.84e-07	2	35	2	12883672
Pubmed	Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.	MET HGF	9.84e-07	2	35	2	1406687
Pubmed	Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mutation.	MET HGF	9.84e-07	2	35	2	12707786
Pubmed	Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway.	MET HGF	9.84e-07	2	35	2	31161784
Pubmed	Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.	MET HGF	9.84e-07	2	35	2	26282167
Pubmed	Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5.	MET HGF	9.84e-07	2	35	2	18992144
Pubmed	Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances.	MET HGF	9.84e-07	2	35	2	24810547
Pubmed	Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met.	MET HGF	9.84e-07	2	35	2	18813782
Pubmed	Structure and expression of mouse aldolase genes. Brain-specific aldolase C amino acid sequence is closely related to aldolase A.	ALDOA ALDOC	9.84e-07	2	35	2	3009179
Pubmed	Distinct projection targets define subpopulations of mouse brainstem vagal neurons that express the autism-associated MET receptor tyrosine kinase.	MET HGF	9.84e-07	2	35	2	28758209
Pubmed	A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.	MET HGF	9.84e-07	2	35	2	18495663
Pubmed	Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.	MET HGF	9.84e-07	2	35	2	1846706
Pubmed	State of the structure address on MET receptor activation by HGF.	MET HGF	9.84e-07	2	35	2	33860789
Pubmed	[Expression of hepatocyte growth factor and its receptor in gastric cancer].	MET HGF	9.84e-07	2	35	2	18024311
Pubmed	Immunoexpression of hepatocyte growth factor and c-Met receptor in the eutopic endometrium predicts the activity of ectopic endometrium.	MET HGF	9.84e-07	2	35	2	12524084
Pubmed	HGF/c-Met signaling promotes liver progenitor cell migration and invasion by an epithelial-mesenchymal transition-independent, phosphatidyl inositol-3 kinase-dependent pathway in an in vitro model.	MET HGF	9.84e-07	2	35	2	26001768
Pubmed	Involvement of hepatocyte growth factor in kidney development.	MET HGF	9.84e-07	2	35	2	8200486
Pubmed	Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis.	MET HGF	9.84e-07	2	35	2	12233882
Pubmed	Disproportionately high levels of HGF induce the degradation of the c-met receptor through the proteasomal degradation pathway.	MET HGF	9.84e-07	2	35	2	30309648
Pubmed	The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.	MET HGF	9.84e-07	2	35	2	30786811
Pubmed	Role of HGF/c-Met in serum-starved ARPE-19 cells.	MET HGF	9.84e-07	2	35	2	18063891
Pubmed	c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.	MET HGF	9.84e-07	2	35	2	14524531
Pubmed	HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.	MET HGF	9.84e-07	2	35	2	19470725
Pubmed	Distinct intracellular signaling mediates C-MET regulation of dendritic growth and synaptogenesis.	MET HGF	9.84e-07	2	35	2	26818605
Pubmed	Structural basis for agonism and antagonism of hepatocyte growth factor.	MET HGF	9.84e-07	2	35	2	20624990
Pubmed	The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma.	MET HGF	9.84e-07	2	35	2	21168200
Pubmed	Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1.	MET HGF	9.84e-07	2	35	2	23123275
Pubmed	Post-ischemic delayed expression of hepatocyte growth factor and c-Met in mouse brain following focal cerebral ischemia.	MET HGF	9.84e-07	2	35	2	14759494
Pubmed	Multiple roles for hepatocyte growth factor in sympathetic neuron development.	MET HGF	9.84e-07	2	35	2	9620689
Pubmed	Cancer-Associated Fibroblasts Promote Radioresistance of Breast Cancer Cells via the HGF/c-Met Signaling Pathway.	MET HGF	9.84e-07	2	35	2	36586496
Pubmed	Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.	MET HGF	9.84e-07	2	35	2	20937841
Pubmed	A role for hepatocyte growth factor during early postimplantation growth of the placental lineage in mice.	MET HGF	9.84e-07	2	35	2	10727259
Pubmed	Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.	MET HGF	9.84e-07	2	35	2	23882082
Pubmed	Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.	MET HGF	9.84e-07	2	35	2	1655405
Pubmed	Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.	MET HGF	9.84e-07	2	35	2	28864680
Pubmed	Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons.	MET HGF	9.84e-07	2	35	2	8982163
Pubmed	Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.	MET HGF	9.84e-07	2	35	2	22276607
Pubmed	Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.	MET HGF	9.84e-07	2	35	2	21796631
Pubmed	Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.	MET HGF	9.84e-07	2	35	2	20019837
Pubmed	Agonist Met antibodies define the signalling threshold required for a full mitogenic and invasive program of Kaposi's Sarcoma cells.	MET HGF	9.84e-07	2	35	2	16039997
Pubmed	A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.	MET HGF	9.84e-07	2	35	2	25212607
Pubmed	Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer.	MET HGF	9.84e-07	2	35	2	22850551
Pubmed	A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.	MET HGF	9.84e-07	2	35	2	17804794
Pubmed	Hepatocyte growth factor protects human embryonic stem cell derived-neural progenitors from hydrogen peroxide-induced apoptosis.	MET HGF	9.84e-07	2	35	2	20655899
Pubmed	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.	MET HGF	9.84e-07	2	35	2	28341789
Pubmed	HGF/MET in osteogenic differentiation of primary human palatal periosteum-derived mesenchymal stem cells.	MET HGF	9.84e-07	2	35	2	34526445
Pubmed	Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway.	MET HGF	9.84e-07	2	35	2	26934743
Pubmed	Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.	MET HGF	9.84e-07	2	35	2	28314274
Pubmed	The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.	MET HGF	9.84e-07	2	35	2	16627020
Pubmed	Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model.	MET HGF	9.84e-07	2	35	2	29203124
Pubmed	Loss of HGF/c-Met signaling in pancreatic β-cells leads to incomplete maternal β-cell adaptation and gestational diabetes mellitus.	MET HGF	9.84e-07	2	35	2	22427375
Pubmed	Differential Immune Checkpoint Protein Expression in HNSCC: The Role of HGF/MET Signaling.	MET HGF	9.84e-07	2	35	2	39000441
Pubmed	Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.	MET HGF	9.84e-07	2	35	2	25502629
Pubmed	Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET.	MET HGF	9.84e-07	2	35	2	14519655
Pubmed	Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor.	MET HGF	9.84e-07	2	35	2	15167892
Pubmed	MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.	MET HGF	9.84e-07	2	35	2	25844809
Pubmed	HGF and c-Met interaction promotes migration in human chondrosarcoma cells.	MET HGF	9.84e-07	2	35	2	23320110
Pubmed	YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells.	MET HGF	9.84e-07	2	35	2	26310485
Pubmed	The impact of c-met/scatter factor receptor on dendritic cell migration.	MET HGF	9.84e-07	2	35	2	12115601
Pubmed	Tumor Specific Recruitment and Reprogramming of Mesenchymal Stem Cells in Tumorigenesis.	MET HGF	9.84e-07	2	35	2	26676563
Pubmed	Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.	MET HGF	9.84e-07	2	35	2	23723997
Pubmed	[Correlation Research on HGF and c-Met of Chronic Erosive Gastritis Patients].	MET HGF	9.84e-07	2	35	2	30650495
Pubmed	MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.	MET HGF	9.84e-07	2	35	2	36799689
Pubmed	Hepatocyte growth factor and c-Met expression in rat and human liver fibrosis.	MET HGF	9.84e-07	2	35	2	15287857
Pubmed	Alteration of angiogenesis in Helicobacter heilmannii-induced mucosa-associated lymphoid tissue lymphoma: interaction with c-Met and hepatocyte growth factor.	MET HGF	9.84e-07	2	35	2	25521737
Pubmed	Analysis of soluble factors in conditioned media derived from primary cultures of cirrhotic liver of biliary atresia.	MET HGF	9.84e-07	2	35	2	28364348
Pubmed	Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy.	MET HGF	9.84e-07	2	35	2	24743740
Pubmed	The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor.	MET HGF	9.84e-07	2	35	2	12847110
Pubmed	A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.	MET HGF	9.84e-07	2	35	2	26093299
Pubmed	Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid.	MET HGF	9.84e-07	2	35	2	18053801
Pubmed	Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.	MET HGF	9.84e-07	2	35	2	26790028
Pubmed	HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics.	MET HGF	9.84e-07	2	35	2	23296269
Pubmed	Met signaling mutants as tools for developmental studies.	MET HGF	9.84e-07	2	35	2	11061428
Pubmed	Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria.	MET HGF	9.84e-07	2	35	2	20375988
Pubmed	Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis.	MET HGF	9.84e-07	2	35	2	21872356
Pubmed	The role of HGF/MET in liver cancer.	MET HGF	9.84e-07	2	35	2	34569818
Pubmed	Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros.	MET HGF	9.84e-07	2	35	2	7822413
Pubmed	Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival.	MET HGF	9.84e-07	2	35	2	22495710
GeneFamily	Actins\|Deafness associated genes	MET HGF TMC1	4.95e-04	113	25	3	1152
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	ZNF317 ZNF582 ZNF518A ZNF566 ZNF44	2.67e-03	718	25	5	28
ToppCell	PND14-Immune-Immune_Myeloid-Granulocytic\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ALDOA ITGB7 ALOX15	4.61e-06	142	35	4	bf3537bec0eca9f90c00df9ba840c371f1c9856e
ToppCell	10x3'2.3-week_14-16-Myeloid_DC-DC-DC1\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	ACE ATP2B1 ITGB7 ALOX15	9.62e-06	171	35	4	459e1ac0b89571c39db98c0f578eca8f46caa8e3
ToppCell	facs-Marrow-T-cells-3m-Myeloid\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET HGF ITGB7 ALOX15	1.20e-05	181	35	4	7286700396676fdc41d9723979b8b408177aceb9
ToppCell	Frontal_cortex-Macroglia-ASTROCYTE-Gja1-Gfap-_astrocytes_(Gja1)\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	ABCB11 HGF ALDOC	6.05e-05	97	35	3	031bc124739541b0b2591e1b6ef41f12adfd5c18
ToppCell	Frontal_cortex-Macroglia-ASTROCYTE-Gja1-Gfap-_astrocytes_(Gja1)-\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	ABCB11 HGF ALDOC	6.05e-05	97	35	3	0cd19f619f10a35d3107518aa83c0eda0572930a
ToppCell	Frontal_cortex-Macroglia-ASTROCYTE-Gja1-Gfap-_astrocytes_(Gja1)--\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	ABCB11 HGF ALDOC	6.05e-05	97	35	3	33330ac2de9e49d78b478f175068999235c9af25
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW23-Mesenchymal-Unfolded_protein_responsible_cell\|GW23 / Sample Type, Dataset, Time_group, and Cell type.	MET FOXRED2 ALOX15	8.10e-05	107	35	3	7fee0193ee02e9cc62f506660ea7ec23fb4d0c84
ToppCell	Myeloid-D_(Mast_cell)\|World / shred on cell class and cell subclass (v4)	HGF ITGB7 ALOX15	1.44e-04	130	35	3	574e262eb4ed2d69c3da68be061cebac9fefc29e
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW16-OPC_related-Oligodendrocyte/OPC\|GW16 / Sample Type, Dataset, Time_group, and Cell type.	ABCB11 ITGB7 RGS22	1.87e-04	142	35	3	43e72e4b9ae33768672ef90c8bbfd2ca1818c746
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW16-OPC_related\|GW16 / Sample Type, Dataset, Time_group, and Cell type.	ABCB11 ITGB7 RGS22	1.87e-04	142	35	3	d2d150e3019a5b7b143e50b1c1c2b6764abf36bf
ToppCell	E18.5-Immune-Immune_Myeloid-Granulocytic\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	2.16e-04	149	35	3	5a5e9660f7d9b527f50a92d94d4c0c8aedb82c0b
ToppCell	PND28\|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ACE ITGB7 STAT1	2.16e-04	149	35	3	d3a025440c8ad284a9291c902403e5888d28e90b
ToppCell	PND10-Immune-Immune_Myeloid-Granulocytic\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	2.16e-04	149	35	3	c9334f319a0c943268e54b6f0c9446736172c3a9
ToppCell	PND07-Immune-Immune_Myeloid-Granulocytic\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	2.38e-04	154	35	3	f92d83c5f8b532fe5624f1cd352632f543d96ea9
ToppCell	367C-Lymphocytic-CD4_T-cell-Treg_cell_1\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	TMC1 RGS22 GPX1	2.61e-04	159	35	3	b05fda31b77536a1878f55d3199563b53f9420b2
ToppCell	367C-Lymphocytic-CD4_T-cell-Treg_cell_1\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	TMC1 RGS22 GPX1	2.61e-04	159	35	3	ae53ab7a1339007d0b245c6c291ac61e5ff5b682
ToppCell	E16.5-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-NK-NK_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ENGASE ITGB7 STAT1	2.66e-04	160	35	3	b2d8940ea8c068273b7da1589d3d6ae5110d8209
ToppCell	E16.5-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ENGASE ITGB7 STAT1	2.66e-04	160	35	3	9caab1bb63c7e66c44783852ee75b16bb40fa594
ToppCell	E16.5-Immune-Immune_Lymphocytic_T/NK\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ENGASE ITGB7 STAT1	2.66e-04	160	35	3	229841be7b984a00a301cd5d88c11226a90d8a88
ToppCell	E16.5-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-NK\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ENGASE ITGB7 STAT1	2.66e-04	160	35	3	99c9ae2041445539fada842e1af01368669bfca0
ToppCell	droplet-Liver-LIVER_HEP-30m-Myeloid-macrophage/monocyte\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZCCHC4 ACE STAT1	2.76e-04	162	35	3	93bd29c52846c3156b8b0d2e39c552373efdfe93
ToppCell	PND14-Immune-Immune_Myeloid-Granulocytic-Basophil\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	2.86e-04	164	35	3	dc22b1fef49c1557a0b63c536eaba574dfcab715
ToppCell	PND14-Immune-Immune_Myeloid-Granulocytic-Basophil-Basophil_mature\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	2.86e-04	164	35	3	f4de9f18134a06f3d7fcf5b50b8e21c1506e2083
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_naive-A\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CPLANE2 ENGASE GPX1	3.01e-04	167	35	3	1cd9e2af85c6c5b9e1d88991c87ac6980b387243
ToppCell	facs-Thymus-Thymus_Flowthrough-18m-Lymphocytic-DN4_thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ALDOA ITGB7 STAT1	3.01e-04	167	35	3	d72b08b3cbc34b30a11dcf512e472b64d1606ec1
ToppCell	facs-Thymus-Thymus_Flowthrough-18m-Lymphocytic-DN4_thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ALDOA ITGB7 STAT1	3.01e-04	167	35	3	22f7384ff2044898d7b0b01cb9d9a3cbaa93a9a3
ToppCell	10x_3'_v2v3-Neoplastic-Differentiated-like-AC-like-AC-like-D\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ALDOC ALOX15 RGS22	3.07e-04	168	35	3	435ef2e4d702e978d54f9d1f5a047f39c691cc63
ToppCell	E18.5-Immune-Immune_Myeloid-Granulocytic-Basophil\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.12e-04	169	35	3	b23d0aaa2da333b9c69a7aee862d5a5d2a1bf79b
ToppCell	E18.5-Immune-Immune_Myeloid-Granulocytic-Basophil-Basophil_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.12e-04	169	35	3	83d1bcf33872b01ea9614f608a3e4ab30df25c7e
ToppCell	droplet-Lung-immune-endo-depleted-3m-Myeloid-non-classical_monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZCCHC4 ACE GPX1	3.17e-04	170	35	3	8e774af244cfe787fa0ea2b6be0c3c2d00bfe4fc
ToppCell	droplet-Lung-immune-endo-depleted-3m-Myeloid-Nonclassical_Monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZCCHC4 ACE GPX1	3.17e-04	170	35	3	f5140eb9313c0d1bb31f8a761d9c062c56733a61
ToppCell	PND07-Immune-Immune_Myeloid-Granulocytic-Basophil\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.17e-04	170	35	3	bca78719c17355772ad6c53ee75e459faf1d089f
ToppCell	PND07-Immune-Immune_Myeloid-Granulocytic-Basophil-Basophil_mature\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.17e-04	170	35	3	40d863554ec98ae43f76511c1112859688846613
ToppCell	Myeloid-Myeloid-D_(Mast_cell)\|Myeloid / shred on cell class and cell subclass (v4)	HGF ITGB7 ALOX15	3.23e-04	171	35	3	5f1aafc4c55a9c6c3153430186a8a351425a3cb9
ToppCell	PND10-Immune-Immune_Myeloid-Granulocytic-Basophil-Basophil_mature\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.28e-04	172	35	3	c05af6e559f6af0fb15cefa03ffa1413e98a1a4a
ToppCell	PND01-Immune-Immune_Myeloid-Granulocytic-Basophil\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.28e-04	172	35	3	6503e85182eb6e8a40a890e393e9ac5c5350e322
ToppCell	PND10-Immune-Immune_Myeloid-Granulocytic-Basophil\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.28e-04	172	35	3	953b05f776348cff784e79c93df65841939d880f
ToppCell	PND01-Immune-Immune_Myeloid-Granulocytic-Basophil-Basophil_mature\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.28e-04	172	35	3	3c0bf7200e582ee730af49dcd86446e112226aca
ToppCell	PND03-Immune-Immune_Myeloid-Granulocytic-Basophil-Basophil_mature\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.34e-04	173	35	3	4282b47b33325472f52a4085986988911a372ed8
ToppCell	droplet-Lung-3m-Hematologic-myeloid-Basophil/Mast_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	HGF ITGB7 ALOX15	3.34e-04	173	35	3	b2c55084ef6dac0e329c2e65c24cfe0045859c30
ToppCell	PND03-Immune-Immune_Myeloid-Granulocytic-Basophil\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.34e-04	173	35	3	8ca650542655c27516029e5bace97ff1b9dcc256
ToppCell	droplet-Lung-3m-Hematologic-myeloid-Basophil/Mast_cell-basophil_l26\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	HGF ITGB7 ALOX15	3.34e-04	173	35	3	120dd20e8a71f9169a1596b6171df7aa0b96dd15
ToppCell	E16.5-Immune-Immune_Myeloid-Granulocytic-Basophil\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.34e-04	173	35	3	2cba41c3d9d3076f703115d19729073a3ac3feb6
ToppCell	E16.5-Immune-Immune_Myeloid-Granulocytic-Basophil-Basophil_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HGF ITGB7 ALOX15	3.34e-04	173	35	3	11d69a4ab4a87b8820cd3bd204de8c4124450a90
ToppCell	Monocytes-IFN-activated_Monocytes\|Monocytes / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	ALDOA ITGB7 STAT1	3.51e-04	176	35	3	6a4b403ee3e4dc4f23fbd7a154011e41fd429a9e
ToppCell	droplet-Fat-Mat-18m-Hematologic-monocyte\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HGF FOXRED2 ALOX15	3.51e-04	176	35	3	867936a20f73f638055c19c8d88834aa2cc657cf
ToppCell	T_cells-Tph_and_Tfh\|T_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	AHI1 STAT1 GPX1	3.51e-04	176	35	3	56c055488e34605d32562571a2fee621b47c9441
ToppCell	droplet-Marrow-BM_(NON-STC)-30m-Myeloid-monocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACE ATP2B1 ITGB7	3.51e-04	176	35	3	1bf8fed48bd224f09efe90a38233b1f01d7311fe
ToppCell	LPS-IL1RA+antiTNF-Myeloid-Monocytes,_Macrophages-Neutrophils\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ALDOA STAT1 GPX1	3.57e-04	177	35	3	2dd6dd5193bda9ba1c6b299ec47890fdc92f88b1
ToppCell	droplet-Marrow-nan-21m-Myeloid-monocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACE ATP2B1 ITGB7	3.57e-04	177	35	3	b860013f1fd397400a62d66ab521cfc81349ffe2
ToppCell	TCGA-Skin-Metastatic-Melanoma-Skin_Cutaneous_Melanoma-5\|TCGA-Skin / Sample_Type by Project: Shred V9	HGF RPGR ATP2B1	3.63e-04	178	35	3	ad5cd505ca1cef8ac29b2af7e2c3e01ebc140c14
ToppCell	droplet-Marrow-nan-24m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HGF ITGB7 ALOX15	3.63e-04	178	35	3	cc0382b0ee1e6c76522e2c86ad1425c45debab5d
ToppCell	facs-Lung-EPCAM-18m-Lymphocytic-lymphocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CPLANE2 ZCCHC4 ITGB7	3.75e-04	180	35	3	67b062f2ef7e20f392e00c646f4985c415d40de9
ToppCell	facs-Lung-EPCAM-18m-Lymphocytic-Alox5+_Lymphocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CPLANE2 ZCCHC4 ITGB7	3.75e-04	180	35	3	b28363626f4d2a552abde3434cc1df2e2121aba5
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_D_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SMARCA1 HGF AHI1	3.75e-04	180	35	3	8bf6e8b6b45ce42f8c5f23e7cd1752ec8b3fa2d2
ToppCell	droplet-Marrow-nan-21m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HGF ITGB7 ALOX15	3.75e-04	180	35	3	41e8155cc7b3dac9d496e4077845ca6af1591a5c
ToppCell	droplet-Marrow-nan-18m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HGF ITGB7 ALOX15	3.81e-04	181	35	3	382337427be3c11ecd03e9fa2c2e831a9674c6a7
ToppCell	droplet-Marrow-nan-3m-Myeloid-promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET USP8 ITGB7	3.87e-04	182	35	3	bc8d621be57f76d718d9b0f11e023b0f4dcb668d
ToppCell	Control-Endothelial-Endothelial-Activated_Alv_Cap\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ACE MAPRE2 STAT1	3.94e-04	183	35	3	e81c142770f44fd902b0631bc360c5b5339d4c75
ToppCell	HSPCs-Eo/Baso_prog.\|HSPCs / Lineage and Cell class	HGF ITGB7 ALOX15	4.06e-04	185	35	3	1ae29c0077bfc57e8896e59a21f20af43e7ff5b7
ToppCell	HSPCs-Eo/Baso_prog.\|World / Lineage and Cell class	HGF ITGB7 ALOX15	4.06e-04	185	35	3	b40ea11f5e536438b400ca5fddfd4559789036bd
ToppCell	droplet-Marrow-BM-30m-Myeloid-promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET ATP2B1 ITGB7	4.13e-04	186	35	3	bcb3ac9f9b51346e0a2b0bda96d149b3c11f7883
ToppCell	P03-Endothelial-large_vessel_endothelial_cell-endothelial_cell_of_artery\|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ACE ALDOC ATP2B1	4.19e-04	187	35	3	66ebe1788d51b3e17bec6cdb219f709756b4e530
ToppCell	10x_3'_v2v3-Neoplastic-Differentiated-like-AC-like-AC-like-A\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	AHI1 ALDOA ATP2B1	4.19e-04	187	35	3	db771e952f71a12886c2dbc77c6cd07054ef809a
ToppCell	P15-Endothelial-large_vessel_endothelial_cell-endothelial_cell_of_artery\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ALDOA ACE ALDOC	4.26e-04	188	35	3	50b27fc12347ca16bd62333baf345c83cb422a8f
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-DC-cDC2-D\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ALDOA ITGB7 ALOX15	4.26e-04	188	35	3	ef3f6400c018834a8fd56893faa3476a0f10aedc
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	USP8 RPGR ATP2B1	4.33e-04	189	35	3	b13f315f617840eb5143a4e8a33a657c20365c21
ToppCell	tumor_Lymph_Node_/_Brain-Fibroblasts-Pericytes\|Fibroblasts / Location, Cell class and cell subclass	RPGR CABIN1 ATP2B1	4.33e-04	189	35	3	f4865b7db16de15120504147a8016ac522ad242a
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_mature-Endo_arterial-C\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ABCB11 RPGR ACE	4.39e-04	190	35	3	06bfb62b94b0faf467ef93d5bc5d08924c770098
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25\|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k)	AHI1 RPGR ATP2B1	4.46e-04	191	35	3	1ecd9849d14d5ebf3daf610e83fb50820cafd3ed
ToppCell	ILEUM-non-inflamed-(2)_B_cell-(2)_Memory_B_cells\|(2)_B_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	ALDOA ATP2B1 ITGB7	4.53e-04	192	35	3	37d0d0fdd6bc3114d546020b472b6df9392392f4
ToppCell	10x3'2.3-week_14-16-Myeloid_DC-DC-DC3\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	ALDOA ITGB7 GPX1	4.53e-04	192	35	3	0e0fbc0bc004dea0db8ccbe81738ab50c0685883
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	AHI1 RPGR ATP2B1	4.67e-04	194	35	3	d852aebf7a763b9a776c4570711f0c759f591910
ToppCell	droplet-Mammary_Gland-nan-21m-Epithelial-luminal_progenitor_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET ALDOC ALOX15	4.67e-04	194	35	3	0ef63abcfd057079a9a6f8b27404ff521d44845d
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Epithelial-luminal_progenitor_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET ALDOC ATP2B1	4.67e-04	194	35	3	550e61a40be2baa59520aaf5912bb99ad094ba15
ToppCell	Differ-Basal\|World / shred by cell class for mouse tongue	ALDOA ALDOC MAPRE2	4.67e-04	194	35	3	851eff82c9f3d44c86e3e127a804bbd1fced6a7c
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	AHI1 RPGR ATP2B1	4.74e-04	195	35	3	481989d2e5bd2582da3d86b0155c4d6615317067
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	AHI1 RPGR ATP2B1	4.74e-04	195	35	3	6108a27523d1b93a7fbe35cb95704a5ad9071e3c
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ATP2B1 ITGB7 GPX1	4.81e-04	196	35	3	a44a648bf209ce037bfc7b3adfcb220aab60728c
ToppCell	B_cell_maturation-Memory_B_cell\|B_cell_maturation / Lineage and Cell class	ALDOA ATP2B1 ITGB7	4.81e-04	196	35	3	869ed6c83dfe0d874ea2bf2e358f54e5011e80e6
ToppCell	suprabasal_cell\|World / shred by cell class for bronchial biopsy	ALDOA ALOX15 GPX1	4.81e-04	196	35	3	3c1fa7ec1c7e02b45b2c5843d2c5b2063cd13be8
ToppCell	Bronchial-NucSeq-Epithelial-Epi_submucosal-gland-SMG_Duct\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MET FOXRED2 ZNF582	4.95e-04	198	35	3	1fe60443c11d34b6d2671af8f06e0dedc8d1558b
ToppCell	ILEUM-inflamed-(6)_ILC-(6)_ILC3\|(6)_ILC / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	ALDOC ITGB7 GPX1	5.03e-04	199	35	3	02879df850b0c72b57d7b22cfc43f3407e182dcb
ToppCell	Severe-B_intermediate-6\|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)	ACE MAPRE2 ITGB7	5.03e-04	199	35	3	bf6ebb63ab361d9d1946225894d7be433e9befab
ToppCell	tumor_Lung-Myeloid_cells-mo-Mac\|Myeloid_cells / Location, Cell class and cell subclass	ACE STAT1 GPX1	5.10e-04	200	35	3	58ff8db0ecf71daa86f9a38208e0d9b712cac0b5
ToppCell	LPS_anti-TNF-Hematopoietic_Myeloid-Granulocytic_cells-Mast-cells\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ZNF582 ITGB7 ALOX15	5.10e-04	200	35	3	0b02f3ca3d8612ed7af46381195b0ed5591313cf
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-10w-Macroglial-Glia_progenitor_cell\|10w / Sample Type, Dataset, Time_group, and Cell type.	MAGT1 ALDOA GPX1	5.10e-04	200	35	3	4859fbe663ae9372fc8ed3b4e1fa301e06621a31
Drug	monomethyl phthalate	SMARCA1 ENGASE ABCB11 HGF ALDOA CABIN1 ALDOC ITGB7 STAT1 GPX1	1.16e-06	957	35	10	ctd:C517284
Drug	bis(sulfosuccinimidyl)suberate	MET HGF	2.30e-06	2	35	2	ctd:C035760
Drug	((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)	MET HGF	2.30e-06	2	35	2	ctd:C478479
Drug	Ichiba acid	ALDOA ALDOC	2.30e-06	2	35	2	CID000440403
Drug	3-HM	ALDOA ALDOC	2.30e-06	2	35	2	CID000439464
Drug	bromohydroxyacetone phosphate	ALDOA ALDOC	2.30e-06	2	35	2	CID000152675
Drug	anthracene diol	ALDOA ALDOC	2.30e-06	2	35	2	CID000155464
Drug	pimagedine	ACE ATP2B1 STAT1 GPX1	3.35e-06	67	35	4	ctd:C004479
Drug	dicyclohexyl phthalate	SMARCA1 ENGASE ABCB11 HGF ALDOA ALDOC ITGB7 STAT1 GPX1	3.47e-06	836	35	9	ctd:C036042
Drug	SureCN2313095	ABCB11 MET HGF STAT1	5.55e-06	76	35	4	CID011840973
Drug	PHA665752	MET HGF STAT1	5.77e-06	23	35	3	CID010461815
Drug	Nitrofurantoin	ABCB11 ALDOA STAT1	6.59e-06	24	35	3	ctd:D009582
Drug	2-keto-3-deoxy- l-lyxonate	ALDOA ALDOC	6.88e-06	3	35	2	CID000192781
Drug	4-fluorothreonine	ALDOA ALDOC	6.88e-06	3	35	2	CID000128057
Drug	(4S,7R,8R,9R,13Z,16S)-4,8-dihydroxy-5,5,7,9-tetramethyl-16-[(E)-1-methyl-2-(2-methylthiazol-4-yl)vinyl]-1-oxacyclohexadec-13-ene-2,6-dione	ALDOA ALDOC	6.88e-06	3	35	2	CID009869661
Drug	acetol phosphate	ALDOA ALDOC	6.88e-06	3	35	2	CID000150865
Drug	androisoxazole	ALDOA ALDOC	6.88e-06	3	35	2	CID000009676
Drug	2-keto-3-bromobutyrate	ALDOA ALDOC	6.88e-06	3	35	2	CID000191968
Drug	3-isochromanone	ALDOA ALDOC	6.88e-06	3	35	2	CID000078092
Drug	3,3,3-trifluoropropanoic acid	ALDOA ALDOC	6.88e-06	3	35	2	CID002777972
Drug	5-deoxy-5-fluoro-L-sorbose	ALDOA ALDOC	6.88e-06	3	35	2	CID000191809
Drug	D-ribulose-1-p	ALDOA ALDOC	6.88e-06	3	35	2	CID000000615
Drug	4-hydroxy-9-fluorenone	ALDOA ALDOC	6.88e-06	3	35	2	CID000016139
Drug	AC1L19ID	ALDOA ALDOC	6.88e-06	3	35	2	CID000000560
Drug	4-hydroxy-2-ketopimelate	ALDOA ALDOC	6.88e-06	3	35	2	CID000000553
Drug	AC1L19F1	ALDOA ALDOC	6.88e-06	3	35	2	CID000000519
Drug	A-1155463	MET HGF	6.88e-06	3	35	2	ctd:C000603579
Drug	Htfp	ALDOA ALDOC	6.88e-06	3	35	2	CID000125055
Drug	DIDIT	ALDOA ALDOC	6.88e-06	3	35	2	CID000196082
Drug	C11 -427	ALDOA ALDOC	6.88e-06	3	35	2	CID000443195
Drug	N-(4-aminobutyl)-2-naphthalenesulfonamide	MET HGF CABIN1	7.48e-06	25	35	3	CID000004298
Drug	1H-n	ALDOA ALDOC ALOX15	9.49e-06	27	35	3	CID000006844
Drug	dimethyl phthalate	ENGASE HGF USP8 STAG1 ALDOC ITGB7 STAT1 GPX1	9.99e-06	714	35	8	ctd:C024629
Drug	Oxalamine citrate salt [1949-20-8]; Down 200; 9.2uM; MCF7; HT_HG-U133A	MET AHI1 RPGR CABIN1 ALOX15	1.04e-05	191	35	5	4969_DN
Drug	9-fluorenone-1-carboxylic acid	ALDOA ALDOC	1.37e-05	4	35	2	CID000074083
Drug	C06441	ALDOA ALDOC	1.37e-05	4	35	2	CID000441020
Drug	formylacetate	ALDOA ALDOC	1.37e-05	4	35	2	CID000075269
Drug	3-hydroxy-1-indanone	ALDOA ALDOC	1.37e-05	4	35	2	CID000176448
Drug	l-123	ALDOA ALDOC	1.37e-05	4	35	2	CID000093552
Drug	dibromoacetonitrile	MET HGF	1.37e-05	4	35	2	ctd:C051715
Drug	phenanthrene trans-3,4-dihydrodiol	ALDOA ALDOC	1.37e-05	4	35	2	CID000119398
Drug	DHMP	ALDOA ALDOC	1.37e-05	4	35	2	CID000098784
Drug	dihydroxyacetone sulfate	ALDOA ALDOC	1.37e-05	4	35	2	CID000439751
Drug	AC1L9A8P	ALDOA ALDOC	1.37e-05	4	35	2	CID000440943
Drug	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	HGF ACE ALOX15 GPX1	1.41e-05	96	35	4	ctd:C080955
Drug	C0107	ALDOA ALDOC ALOX15	1.76e-05	33	35	3	CID000018639
Drug	pH x	ABCB11 MET HGF	1.93e-05	34	35	3	CID011967789
Drug	1,3-dioxan-5-one	ALDOA ALDOC	2.29e-05	5	35	2	CID009793707
Drug	AC1L4F2K	ALDOA ALDOC	2.29e-05	5	35	2	CID000184526
Drug	alpha-methylserine	ALDOA ALDOC	2.29e-05	5	35	2	CID000094309
Drug	gamma-oxalocitramalate	ALDOA ALDOC	2.29e-05	5	35	2	CID000000130
Drug	Akt inhibitor X	MET HGF	2.29e-05	5	35	2	CID010521421
Drug	phosphoglycollamide	ALDOA ALDOC	2.29e-05	5	35	2	CID000191768
Drug	D-erythrulose 1-phosphate	ALDOA ALDOC	2.29e-05	5	35	2	CID000152153
Drug	2,3-dihydroxy-p-cumate	ALDOA ALDOC	2.29e-05	5	35	2	CID000029587
Drug	f-3p	ALDOA ALDOC	2.29e-05	5	35	2	CID015991581
Drug	CB 3717	MET HGF	2.29e-05	5	35	2	ctd:C031662
Drug	AC1NX490	ALDOA ALDOC	2.29e-05	5	35	2	CID005743230
Drug	hydroxypyruvaldehyde phosphate	ALDOA ALDOC	2.29e-05	5	35	2	CID000193787
Drug	Valsartan	HGF ACE STAT1 ALOX15	3.28e-05	119	35	4	ctd:D000068756
Drug	mycestericin D	ALDOA ALDOC	3.43e-05	6	35	2	CID006439504
Drug	E 4177	HGF ACE	3.43e-05	6	35	2	CID000131857
Drug	2,2-dimethyl-1,3-dioxan-5-one	ALDOA ALDOC	3.43e-05	6	35	2	CID002733141
Drug	2-(N-decyl)aminonaphthalene-6-sulfonic acid	ALDOA ALDOC	3.43e-05	6	35	2	CID000189836
Drug	propyltrimethoxysilane	ALDOA ALDOC	3.43e-05	6	35	2	CID000061254
Drug	AC1L18Q4	ALDOA ALDOC	3.43e-05	6	35	2	CID000000210
Drug	parapyruvate	ALDOA ALDOC	3.43e-05	6	35	2	CID000440249
Drug	7-oxoheptanoic acid	ALDOA ALDOC	3.43e-05	6	35	2	CID000169732
Drug	acetyldithio-CoA	ALDOA ALDOC	3.43e-05	6	35	2	CID003082679
Drug	0 Gz	ALDOA ALDOC	3.43e-05	6	35	2	CID000000372
Drug	chloroacetol phosphate	ALDOA ALDOC	3.43e-05	6	35	2	CID000168137
Drug	C02783	ALDOA ALDOC	3.43e-05	6	35	2	CID000439805
Drug	benzyloxyacetaldehyde	ALDOA ALDOC	3.43e-05	6	35	2	CID000108989
Drug	5-deoxy-D-xylulose-1-phosphate	ALDOA ALDOC	4.80e-05	7	35	2	CID000192931
Drug	2-indanone	ALDOA ALDOC	4.80e-05	7	35	2	CID000011983
Drug	Z-Glu-Tyr	ALDOA ALDOC	4.80e-05	7	35	2	CID000096820
Drug	acenaphthenone	ALDOA ALDOC	4.80e-05	7	35	2	CID000075229
Drug	carboxylin	ALDOA ALDOC	4.80e-05	7	35	2	CID003082458
Drug	Diethyl Pyrocarbonate	MET HGF	4.80e-05	7	35	2	ctd:D004047
Drug	C0447	ALDOA ALDOC	4.80e-05	7	35	2	CID000128786
Drug	B-N6	ALDOA ALDOC	4.80e-05	7	35	2	CID015942653
Drug	glycidol phosphate	ALDOA ALDOC	4.80e-05	7	35	2	CID000152659
Drug	DAPpNP	ALDOA ALDOC	4.80e-05	7	35	2	CID005492375
Drug	3-hydroxy-4-oxobutyl-1-phosphonate	ALDOA ALDOC	6.39e-05	8	35	2	CID003016813
Drug	L-rhamnulose-1-phosphate	ALDOA ALDOC	6.39e-05	8	35	2	CID000439413
Drug	amorphin	ALDOA ALDOC	6.39e-05	8	35	2	CID000122792
Drug	macrophomate	ALDOA ALDOC	6.39e-05	8	35	2	CID010889109
Drug	AC1L1K98	ABCB11 CABIN1 ACE	7.40e-05	53	35	3	CID000005393
Drug	3'-Me-DAB	HGF ALDOA ALDOC	7.82e-05	54	35	3	CID000005934
Drug	AC1Q6BTB	ALDOA ALDOC	8.21e-05	9	35	2	CID000000080
Drug	2-oxopentenoate	ALDOA ALDOC	8.21e-05	9	35	2	CID000000976
Drug	compound 48/80	ENGASE ACE ATP2B1 ALOX15	8.29e-05	151	35	4	CID000104735
Drug	1,2-dihydroxynaphthalene	ALDOA ALDOC ALOX15	9.20e-05	57	35	3	CID000011318
Drug	3,4-dihydro-2(1H)-quinolinone	ALDOA ALDOC	1.03e-04	10	35	2	CID000064796
Drug	tartronate semialdehyde	ALDOA ALDOC	1.03e-04	10	35	2	CID000001122
Drug	L-fuconic acid	ALDOA ALDOC	1.03e-04	10	35	2	CID000345732
Drug	SM-8	ALDOA ALDOC	1.03e-04	10	35	2	CID000486037
Drug	B-42	MET HGF	1.03e-04	10	35	2	CID000118449
Drug	xylonate	ALDOA ALDOC	1.03e-04	10	35	2	CID000010264
Drug	Ab34	ALDOA ALDOC	1.25e-04	11	35	2	CID006449128
Disease	gestational diabetes (implicated_via_orthology)	MET GPX1	1.21e-06	2	33	2	DOID:11714 (implicated_via_orthology)
Disease	Hepatitis, Chronic	MET HGF GPX1	1.93e-06	22	33	3	C0019189
Disease	Chronic active hepatitis	MET HGF GPX1	1.93e-06	22	33	3	C0520463
Disease	Cryptogenic Chronic Hepatitis	MET HGF GPX1	1.93e-06	22	33	3	C0524611
Disease	Chronic Persistent Hepatitis	MET HGF GPX1	1.93e-06	22	33	3	C0149519
Disease	breast cancer (implicated_via_orthology)	MET TRIAP1 STAT1	2.88e-06	25	33	3	DOID:1612 (implicated_via_orthology)
Disease	Neoplasm Metastasis	MET HGF ALDOA ACE STAT1	4.12e-06	217	33	5	C0027627
Disease	multiple myeloma (is_implicated_in)	MET ACE GPX1	3.97e-05	59	33	3	DOID:9538 (is_implicated_in)
Disease	Hypertensive disease	ACE ATP2B1 ALOX15 GPX1	5.89e-05	190	33	4	C0020538
Disease	Copper-Overload Cirrhosis	MET HGF	6.63e-05	11	33	2	C1876165
Disease	pulmonary fibrosis (implicated_via_orthology)	ACE STAT1	7.95e-05	12	33	2	DOID:3770 (implicated_via_orthology)
Disease	cholangiocarcinoma (biomarker_via_orthology)	MET HGF	9.39e-05	13	33	2	DOID:4947 (biomarker_via_orthology)
Disease	leukemia (is_implicated_in)	ACE GPX1	9.39e-05	13	33	2	DOID:1240 (is_implicated_in)
Disease	Nonsyndromic Deafness	MET HGF TMC1	1.02e-04	81	33	3	C3711374
Disease	anemia (is_implicated_in)	ACE GPX1	1.09e-04	14	33	2	DOID:2355 (is_implicated_in)
Disease	hearing impairment	RPGR TMC1 STAT1	1.80e-04	98	33	3	C1384666
Disease	Autistic Disorder	MET AHI1 ACE GPX1	2.00e-04	261	33	4	C0004352
Disease	Retinal Degeneration	AHI1 RPGR	2.51e-04	21	33	2	C0035304
Disease	factor VIII measurement, coronary artery disease	STAG1 MAPRE2 ATP2B1	2.74e-04	113	33	3	EFO_0001645, EFO_0004630
Disease	Cerebral Astrocytoma	MET HGF	3.58e-04	25	33	2	C0750935
Disease	Intracranial Astrocytoma	MET HGF	3.58e-04	25	33	2	C0750936
Disease	Pilocytic Astrocytoma	MET HGF	3.58e-04	25	33	2	C0334583
Disease	Astrocytoma	MET HGF	3.58e-04	25	33	2	C0004114
Disease	Juvenile Pilocytic Astrocytoma	MET HGF	3.58e-04	25	33	2	C0280783
Disease	Diffuse Astrocytoma	MET HGF	3.58e-04	25	33	2	C0280785
Disease	Grade I Astrocytoma	MET HGF	3.58e-04	25	33	2	C1704230
Disease	Subependymal Giant Cell Astrocytoma	MET HGF	3.58e-04	25	33	2	C0205768
Disease	Mixed oligoastrocytoma	MET HGF	3.58e-04	25	33	2	C0547065
Disease	Childhood Cerebral Astrocytoma	MET HGF	3.58e-04	25	33	2	C0338070
Disease	Squamous cell carcinoma	MET HGF GPX1	3.60e-04	124	33	3	C0007137
Disease	Gemistocytic astrocytoma	MET HGF	3.88e-04	26	33	2	C0334581
Disease	Protoplasmic astrocytoma	MET HGF	3.88e-04	26	33	2	C0334580
Disease	Fibrillary Astrocytoma	MET HGF	3.88e-04	26	33	2	C0334582
Disease	Anaplastic astrocytoma	MET HGF	4.18e-04	27	33	2	C0334579
Disease	gastric adenocarcinoma (is_marker_for)	STAT1 GPX1	4.50e-04	28	33	2	DOID:3717 (is_marker_for)
Disease	arteriosclerosis (is_marker_for)	MET HGF	4.83e-04	29	33	2	DOID:2349 (is_marker_for)
Disease	myocardial infarction (is_marker_for)	HGF GPX1	6.27e-04	33	33	2	DOID:5844 (is_marker_for)
Disease	Cardiovascular Diseases	ACE GPX1	7.46e-04	36	33	2	C0007222
Disease	tongue squamous cell carcinoma (is_marker_for)	MET HGF	7.88e-04	37	33	2	DOID:0050865 (is_marker_for)
Disease	Combined immunodeficiency	MAGT1 STAT1	9.68e-04	41	33	2	C0494261
Disease	liver cirrhosis (is_implicated_in)	ABCB11 ACE	1.06e-03	43	33	2	DOID:5082 (is_implicated_in)
Disease	hepatocellular carcinoma (is_implicated_in)	MET ACE GPX1	1.08e-03	181	33	3	DOID:684 (is_implicated_in)

Protein segments in the cluster

Peptide	Gene	Start	Entry
AWDFYNGKDFRIKQC	ACE	961	P12821
NQECGFRKIAWAFLK	AHI1	466	Q8N157
AQYKKDGADFAKWRC	ALDOC	136	P09972
AQYKKDGADFAKWRC	ALDOA	136	P04075
CRNDVAWNFEKFLVG	GPX1	156	P07203
WDNFQGKIDFVDCKF	ABCB11	1071	O95342
AFNDWSKEKQFRGLQ	ATP2B1	171	P20020
FLKGNCANKEDTWKF	MAGEB5	141	Q9BZ81
EFLFNKTGWAFAALC	MAGT1	211	Q9H0U3
EKFRKDLCRFWSNVF	GINM1	246	Q9NU53
DDFNRIFWCGQSKLA	ALOX15	201	P16050
AFVFDKARKQCLWFP	HGF	86	P14210
IFWFNLKEIDFNACL	OR52N2	86	Q8NGI0
IRCLGWNFDFSIFNK	FOXRED2	336	Q8IWF2
GWCKERTLDNQLFFF	ITGB7	686	P26010
ALCSQRFDDWKEKFG	HFM1	341	A2PYH4
RFEFWDCGESALKKF	CPLANE2	111	Q9BU20
LFCERNKTNFFNGIW	CABIN1	1571	Q9Y6J0
KGRFQDNLDFIQWFK	MAPRE2	141	Q15555
EKKDFFQNQDKFWGR	ENGASE	371	Q8NFI3
KFAENNPGKFWFKND	RPGR	21	Q92834
WDFGFRRNNKFDLKK	MET	586	P08581
RFCKENINDKNFPFW	STAT1	541	P42224
CVRNAPQFRFDWFIK	SMARCA1	991	P28370
VLFKFWPQFCEFRKN	RGS22	1126	Q8NE09
FLRDFENFKAACVPW	TMC1	156	Q8TDI8
DQCFNRWFAEKFLKG	TRIAP1	16	O43715
WKKFRSNFCEFIGVL	STAG1	171	Q8WVM7
KAKFNCWFCGRVFDN	ZNF518A	1446	Q6AHZ1
FGYNKCRKDFWQKEL	ZNF582	171	Q96NG8
KDCNFFQWEDEKLSG	ZCCHC4	71	Q9H5U6
SSFRDDWECNRQFKK	ZNF566	116	Q969W8
YCKNAARQRWFKFDD	USP8	1071	P40818
QCGKAFRWKSNFNLH	ZNF317	366	Q96PQ6
ECKQCRKAFFWPSFL	ZNF44	581	P15621